Biogen Idec (BIIB)
249.59
+2.46 (1.00%)
NASDAQ · Last Trade: Nov 20th, 11:11 PM EST
Detailed Quote
| Previous Close | 247.13 |
|---|---|
| Open | 248.74 |
| Bid | 247.00 |
| Ask | 253.00 |
| Day's Range | 248.04 - 253.00 |
| 52 Week Range | 160.36 - 261.00 |
| Volume | 1,132,508 |
| Market Cap | 36.64B |
| PE Ratio (TTM) | 107.58 |
| EPS (TTM) | 2.3 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 1,196,222 |
Chart
About Biogen Idec (BIIB)
Biogen is a global biotechnology company dedicated to discovering, developing, and delivering innovative therapies for neurological and neurodegenerative diseases. The company focuses on addressing serious conditions such as multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy, among others. Through advanced research and development, Biogen aims to create breakthrough treatments that improve the lives of patients and their families, and it leverages its expertise in biologics and immunology to bring novel solutions to market. Additionally, Biogen is committed to advancing science and fostering collaboration within the medical and scientific communities to further enhance patient care. Read More
News & Press Releases
Biogen (NASDAQ:BIIB) expects to announce results from two systemic lupus erythematosus trials together in a press release, as the company prepares for a series of pipeline readouts and seeks to return to revenue growth, President and Head of North America Alisha Alaimo said at a Jefferies conference
Via MarketBeat · November 17, 2026
Late-stage trials could reshape the rare disease franchise, but the real story is whether the pipeline matters at all.
Via The Motley Fool · November 17, 2026
CAMBRIDGE, Mass., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data from the Phase 2 CELIA study showing increasing clinical benefit of diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in people living with early Alzheimer's disease at two years (Week 96). Results presented at the Clinical Trials on Alzheimer's Disease (CTAD) 2026 conference showed slowing of clinical decline across measures of cognition, function and disease progression, with the 60 mg twice-yearly regimen showing the largest treatment effects at two years.
By Biogen Inc. · Via GlobeNewswire · November 17, 2026
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.chartmill.com
Via Chartmill · October 12, 2026
The stock has climbed more than 40% in one year.
Via The Motley Fool · November 14, 2026
BRUSSELS and CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced further data characterizing the clinical profile of dapirolizumab pegol (DZP), an investigational biologic for people living with systemic lupus erythematosus (SLE). The data are being presented across five posters at ACR Convergence 2026, the annual meeting of the American College of Rheumatology, in Orlando, Florida, November 6-11.
By Biogen Inc. · Via GlobeNewswire · November 9, 2026
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...
Via StockStory · November 5, 2026
CAMBRIDGE, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced it will present new data across its Alzheimer’s disease portfolio at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, taking place November 16–19, 2026, at the Boston Marriott Copley Place in Boston, Massachusetts. Presentations will include expanded data from the Phase 2 CELIA study evaluating diranersen, an investigational tau-targeting antisense oligonucleotide (ASO), and new analyses from studies of lecanemab (brand name: LEQEMBI®).
By Biogen Inc. · Via GlobeNewswire · October 29, 2026
Biogen (NASDAQ:BIIB) reported third-quarter 2026 revenue growth of 11% year over year, supported by its acquisition of Apellis and continued expansion of its growth-product portfolio. Management said the company remains on track to return to top-line growth in 2026 and raised the lower end of its fu
Via MarketBeat · October 28, 2026
Growth portfolio revenue jumped 49%, now 63% of core pharma sales.
Via The Motley Fool · October 28, 2026
Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q3 2026, with revenue up 10.6% year on year to $2.80 billion. Its non-GAAP pro...
Via StockStory · October 28, 2026
Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results this Wednesday before market open. Here’s what to look for. Biogen beat analysts’ re...
Via StockStory · October 26, 2026
S&P 500 Top Movers: Gainers and Losers From Today's US Sessionchartmill.com
Via Chartmill · October 20, 2026
CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new EMPAVELI® (pegcetacoplan) data and additional scientific presentations from its nephrology portfolio, including investigational felzartamab, at the American Society of Nephrology (ASN) Kidney Week taking place from October 22 to 25, 2026 in Denver, Colorado.
By Biogen Inc. · Via GlobeNewswire · October 19, 2026
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the biotechnology industry, including Regeneron (NASDAQ:REGN) and...
Via StockStory · October 14, 2026
Discover which S&P500 stocks are making waves on Monday.chartmill.com
Via Chartmill · October 12, 2026
What Happened? Shares of biotech company Biogen (NASDAQ:BIIB) jumped 3.5% in the pre-market session after JPMorgan upgraded the stock to Overweight from Neut...
Via StockStory · October 12, 2026
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorab...
Via StockStory · October 12, 2026
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD)...
Via StockStory · October 7, 2026
CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced 52-week results from the Phase 2 part of the ongoing AMETHYST Phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE). The updated results, presented at the European Academy of Dermatology and Venereology (EADV) 2026 Congress in Vienna, Austria, represent the longest dataset reported for litifilimab in CLE and further support its potential to achieve rapid and durable improvements in skin disease activity. In the study, participants treated with litifilimab in the double-blind, placebo-controlled period showed continued clinical improvements in skin disease activity through Week 52. Notably, participants who switched from placebo to litifilimab treatment at Week 24 experienced a rapid onset of treatment effect as early as four weeks.
By Biogen Inc. · Via GlobeNewswire · October 2, 2026
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
Via StockStory · October 1, 2026
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Halozyme Therapeutics (NASDAQ:HALO) and its peers. O...
Via StockStory · September 30, 2026
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Bioge...
Via StockStory · September 24, 2026
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking a...
Via StockStory · September 23, 2026
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its pe...
Via StockStory · September 21, 2026
